Abstract
The electrocardiogram (ECG) is the most commonly used exam for the screening and evaluation of cardiovascular diseases. Here we propose that the age predicted by artificial intelligence (AI) from the raw ECG tracing (ECG-age) can be a measure of cardiovascular health and provide prognostic information. A deep convolutional neural network was trained to predict a patient’s age from the 12-lead ECG using data from patients that underwent an ECG from 2010 to 2017 - the CODE study cohort (n=1,558,415 patients). On the 15% hold-out CODE test split, patients with ECG-age more than 8 years greater than chronological age had a higher mortality rate (hazard ratio (HR) 1.79, p<0.001) in a mean follow-up of 3.67 years, whereas those with ECG-age more than 8 years less than chronological age had a lower mortality rate (HR 0.78, p<0.001). Similar results were obtained in the external cohorts ELSA-Brasil (n=14,236) and SaMi-Trop (n=1,631). The ability to predict mortality from the ECG predicted age remains even when we adjust the model for cardiovascular risk factors. Moreover, even for apparent normal ECGs, having a predicted ECG-age 8 or more years greater than chronological age remained a statistically significant predictor of risk (HR 1.53, p<0.001 in CODE 15% test split). These results show that AI-enabled analysis of the ECG can add prognostic information to the interpretation of the 12-lead ECGs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was partly supported by the Brazilian Agencies CNPq, CAPES, and FAPEMIG, by projects IATS, INCT-Cyber and Atmosphere, and by the Wallenberg AI, Autonomous Systems and Software Program (WASP) funded by Knut and Alice Wallenberg Foundation. The ELSA-Brasil‐Brasil study was supported by the Brazilian Ministries of Health and of Science and Technology (grants 01060010.00RS, 01060212.00BA, 01060300.00ES, 01060278.00MG, 01060115.00SP, and 01060071.00RJ). 5U19AI098461-07). The SaMi‐Trop cohort study is supported by the National Institutes of Health (P50 AI098461‐02 and U19AI098461‐06). AHR, BBD, PAL, SMB, LG, WMJr, and ALR are recipients of unrestricted research scholarships from CNPq; EMS and AHR received scholarships from CAPES and CNPq; and DMO, WMJr and ALPR received a Google Latin America Research Award scholarship. None of the funding agencies had any role in the design, analysis or interpretation of the study. We also thank NVIDIA for awarding our project with a Titan V GPU.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study complies with all relevant ethical regulations. CODE Study was approved by the Research Ethics Committee of the Universidade Federal de Minas Gerais, protocol 49368496317.7.0000.5149. Since this is a secondary analysis of anonymized data stored in the TNMG, informed consent was not required by the Research Ethics Committee for the present study. ELSA-Brasil was approved by the Research Ethics Committees of the participating institutions and by the National Committee for Research Ethics (CONEP 976/2006) of the Ministry of Health. Sami-Trop study was approved by the Brazilian National Institutional Review Board (CONEP), No. 179.685/2012. In both investigations, all human subjects were adults who gave written informed consent. All researchers who deal with datasets signed terms of confidentiality and data utilization.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Upon publication, some of the cohorts used in the model evaluation will be made available. Information about mortality, age, sex, the ECG tracings and the flag indicating whether the ECG tracing is normal will be made available with no restriction for the Sami-Trop cohort and for the CODE-15% cohorts. The DNN model parameters that give the results presented in this paper will also be made available without restrictions. This should allow the reader to partially reproduce the results presented in the paper. Restrictions apply to additional clinical information on these two cohorts, to the full CODE cohort and to the ELSA-Brasil cohort, for which requests will be considered on an individual basis by the Telehealth Network of Minas Gerais and by ELSA-Brasil Steering Committee. Any data use will be restricted to non-commercial research purposes, and the data will only be made available on the execution of appropriate data use agreements.
